Latest news with #HLA
Al Etihad
25-05-2025
- Business
- Al Etihad
Abu Dhabi poised to lead in stem cell therapy, research with cutting-edge biobank
25 May 2025 23:17 SARA ALZAABI (ABU DHABI)With a state-of-the-art biobank located in Masdar City, Abu Dhabi is positioning itself as a regional leader in stem cell therapy and biomedical research, eventually eliminating the need for UAE citizens and residents to seek personalised, life-saving treatments Abu Dhabi Biobank is the region's largest multi-modal cord blood collection and storage facility. It offers private cord blood banking services at a fraction of prevailing market rates and also functions as a pan-human biobank, a world-class resource supporting biomedical innovation and personalised healthcare.'The ambition is to do something similar (to the UK Biobank) in Abu Dhabi: Following large numbers of people throughout their lives, understanding their lifestyles, their genetics, their occupation and the other things that influence their health and try to really unpick those details as to what is protective of health and what is deleterious to health,' said Paul Downey, General Manager of Abu Dhabi Biobank, M42, in an interview with collecting umbilical cord blood through its private services, the facility also stores donated samples from families who chose to contribute rather than discard the tissue. To date, more than 1,000 units have been banked — potentially life-saving resources for patients in need of stem cell treatment within the UAE or across the region.'At the moment, people are travelling overseas for stem cell therapy to Europe and the US.' But this could be a compromise, Downey stressed, 'because the stem cell unit you will receive in London or New York will not be as closely genetically matched as if it were a stem cell unit donated in Abu Dhabi'.With the support of the Department of Health – Abu Dhabi, the biobank uses HLA typing to ensure the best biological match between donors and recipients, maximising success rates and minimising rejection.'People from the same ethnicity, same background, have a closer HLA match than somebody living in the UK, the US or Southeast Asia. So, it is important to collect stem cells locally, which is obviously what we're doing,' Downey cell therapy is still considered an emerging field of medicine. 'It falls under the category of regenerative medicine, and I think it is particularly interesting in the fact that it can treat a wide range of diseases.'Currently, umbilical cord blood is used to treat more than 80 serious conditions, but this number is bound to increase, he added. Expanding Stem Cell TreatmentsAbu Dhabi Biobank's dual approach — encompassing both therapeutic and research functions — is what sets it apart. 'We help facilitate stem cell research into how the stem cells can be used to treat other diseases where it is not currently licensed, so through clinical trials,' Downey biobank's research arm supports studies to expand stem cell treatments beyond the current 80 approved vision aligns closely with the work of the Omics Centre of Excellence, another cornerstone of Abu Dhabi's scientific ecosystem.'The Omics Centre of Excellence focuses on human genetics and, in particular, the Emirati Genome Programme and whole genome sequences in general,' Downey genetics is just one layer of the picture. 'Health and disease are a function of your genetics, but also your lifestyle, your occupation, the decisions that you make, things that you are exposed to, pollution, etc. So to understand health and disease, you need access to genetic information and exposure information.' Successful Transplant Eyed This YearFor Downey, Abu Dhabi's biobank is not just about research, it is about health transformation. 'By catalysing biomedical research through the development of this research resource, we will encourage investment in health innovation within the region.'There is, in fact, a growing interest from major pharmaceutical companies, he said.'We are helping facilitate that by developing the resources they need to do their research and biomedical innovation development,' Downey said, pointing to the bank's tumour samples, electronic medical records, and exposure data as major year, Abu Dhabi Biobank is hoping to 'successfully enable a transplant in Abu Dhabi'. 'If we come together, we can make a difference in the world and help develop the Abu Dhabi Biobank. We will surely see innovations, beneficial to people locally, but globally. Those innovations will arise within Abu Dhabi, which is extremely exciting,' Downey said.
Yahoo
22-05-2025
- Health
- Yahoo
Human Leukocyte Antigen (HLA) Typing for Transplant Market worth US$1.4 billion by 2030 with 6.0% CAGR
DELRAY BEACH, Fla., May 22, 2025 /PRNewswire/ -- The global Human Leukocyte Antigen (HLA) Typing for Transplant, valued at US$1.0 billion in 2024, is forecasted to grow at a robust CAGR of 6.0 %, reaching US$1.1 billion in 2025 and an impressive US$1.4 billion by 2030. The escalating demand for organ transplants, which is a prime market driver, is closely associated with lifestyle and occupational risk factors. Sedentary behaviour, poor dietary habits, obesity, diabetes mellitus, and hypertension significantly contribute to the prevalence of chronic kidney and liver diseases. The detrimental effects of alcohol consumption and tobacco use lead to liver cirrhosis and exacerbate COPD, thereby increasing the necessity for liver and lung transplants. Furthermore, occupational exposure to industrial toxins, particularly seen in mining and manufacturing sectors, can result in significant hepatic and pulmonary damage. An aging workforce, coupled with an uptick in cardiovascular morbidity, further intensifies the demand for heart transplants. These trends highlight the critical role of HLA typing in facilitating donor-recipient compatibility, which is essential for improving transplant success rates. Download PDF Brochure: Browse in-depth TOC on "HLA Typing for Transplant Market" 250 - Tables50 - Figures350 - Pages By Based on product & service, the HLA typing market for transplants is categorized into three segments: software & services, reagents &consumables, and instruments. In 2024, the reagents & consumables segment led in global market share; this growing prominence is primarily driven by a rising demand for precise and rapid identification of HLA alleles, which play a crucial role in transplantation procedures. The ability to quickly and accurately determine HLA compatibility ensures successful organ transplants. It minimizes the risk of rejection, which, in turn, highlights the critical need for advanced reagents and consumables. As healthcare providers increasingly prioritize efficient transplantation processes and improved patient outcomes, this segment is expected to grow substantially, fueled by ongoing innovations and advancements in molecular biology techniques. Such developments will further enhance the effectiveness and reliability of HLA typing, making this an exciting area for investment and development in the coming years. By Based on technology, HLA typing for transplantation is categorized into two main segments: molecular assays and non-molecular assays. The molecular-based assays segment commands a significant market share, primarily due to the extensive implementation of advanced molecular technologies, including next-generation sequencing (NGS) and polymerase chain reaction (PCR) methodologies, in transplant facilities and healthcare institutions. These molecular techniques offer superior resolution in HLA typing compared to conventional serological methods, enhancing the accuracy and reliability of donor-recipient matching. By end user, the HLA typing for the transplant market is categorized into independent reference laboratories, hospitals & transplant centers, and research laboratories & academic institutes. In 2024, independent reference laboratories dominated the HLA typing segment of the transplant market due to their ability to handle high sample throughput effectively and specialized expertise in conducting intricate HLA tests and accurately interpreting the results. Their commitment to delivering superior quality HLA typing services further solidified their position in this sector. By geography, in 2022, North America held the predominant share of the HLA typing market for transplant, followed closely by Europe. The Asia Pacific region is expected to experience the most rapid growth in this sector throughout the forecast period. North America's supremacy in the HLA typing market can be attributed to several factors: a significant increase in organ transplantation procedures, a robust presence of companies providing transplant diagnostic products—including HLA typing services—and an upsurge in collaborative research efforts aimed at identifying novel HLA genes and elucidating their implications in organ transplantation. Request Sample Pages : Thermo Fisher Scientific (US), Illumina, Inc. (US), QIAGEN (Germany), CareDx, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Immucor, Inc. (US), Werfen (US), TBG Biotechnology Corporation (Taiwan), Fujirebio (Japan), Omixon Inc. (US), GenDX (Netherlands), BAG Diagnostics GmbH (Germany), Creative Biolabs (US), and PacBio (US) Thermo Fisher Scientific (US): Thermo Fisher Scientific is a preeminent entity in the domain of HLA typing for transplant applications, driven by strategic investments and a robust growth trajectory in this sector. The company provides extensive offerings encompassing PCR-based assays, advanced sequencing technologies, and comprehensive software solutions tailored for HLA typing. This diverse product portfolio meets the varied requirements of transplant centers and laboratories, ensuring optimized workflows and enhanced accuracy. To maintain its competitive edge, Thermo Fisher prioritizes R&D, continually advancing its HLA typing technologies; this unwavering commitment to innovation enhances its product capabilities and positions it at the forefront of the industry, delivering cutting-edge solutions that address the evolving needs of the transplant immunology landscape. QIAGEN (Germany): QIAGEN provides extensive products and solutions tailored for HLA typing, encompassing PCR-based assays, next-generation sequencing (NGS) platforms, and associated reagents. This robust product portfolio positions QIAGEN to effectively meet the varied demands of transplant centers and clinical laboratories. QIAGEN's NGS-based offerings, such as the QIAseq HLA Typing Panel, invest significantly in developing cutting-edge technologies for HLA typing and delivering high-resolution and precise HLA typing results. These advancements enhance transplant matching efficacy and overall patient outcomes. With a strong global market presence, QIAGEN leverages a comprehensive network of distribution channels and strategic partnerships across multiple regions, enabling it to serve a diverse clientele of transplant centers and laboratories worldwide. Strategic acquisitions and collaborations have fortified QIAGEN's standing in the market. Notably, the acquisition of N-of-One, Inc. has expanded its capabilities in precision medicine and clinical decision support, with significant implications for transplantation applications. Additionally, QIAGEN offers customizable products that accommodate the specific requirements of individual laboratories and transplant centers, providing flexibility that appeals to a broad spectrum of customers. The company frequently collaborates with research institutions and organizations engaged in transplantation research, further reinforcing its commitment to advancing the field. Illumina, Inc. (US): Illumina, Inc. is a leading entity in genomics, particularly noted for its advancements in HLA typing for transplantation. Its DNA sequencing platforms, including the HiSeq and NovaSeq systems, are implemented in HLA typing protocols due to their high throughput, precision, and scalability, which are crucial for extensive HLA typing endeavors. As a pioneer in next-generation sequencing (NGS) technology, Illumina has significantly transformed HLA typing methodologies, enabling high-resolution typing that enhances donor-recipient matching and, subsequently, transplant success rates. The company has engaged in strategic collaborations with various organizations within transplantation research and diagnostics, fostering innovation and broadening the scope of its sequencing technologies. Continuous R&D investments have been a hallmark of Illumina's operation, focusing on creating specialized assays and workflows tailored specifically for HLA typing and transplantation research applications. Illumina's sequencing technologies are employed in research and clinical laboratories globally, allowing the company to support transplant centers, hospitals, and research institutions worldwide, which has propelled its expansion in the HLA typing sector. Furthermore, Illumina provides an array of bioinformatics tools and software that help analyze and interpret HLA data, extracting meaningful insights from the extensive datasets generated during HLA typing procedures. For more information, Inquire Now! Related Reports: PCR Technologies Market Digital PCR (dPCR) and Real-time PCR (qPCR) Market Next-Generation Sequencing Market Biomarkers Market Bioinformatics Market Get access to the latest updates on HLA Typing for Transplant Companies and HLA Typing for Transplant Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets
Yahoo
20-05-2025
- Business
- Yahoo
Applied StemCell Launches Two New Hypoimmunogenic hiPSC Products to Accelerate Allogeneic Cell Therapy Development
MILPITAS, Calif., May 20, 2025--(BUSINESS WIRE)--Applied StemCell, a CRO/CDMO that blends unique genome editing technology and iPSC expertise, announced the launch of their first hypoimmunogenic hiPSC products which are designed to empower researchers developing next-generation allogeneic cell therapies. The ActiCells™ RUO Hypo hiPSCs (Cat.# ASE-9550) and the ActiCells™ RUO TARGATT™ Hypo hiPSC Knock-in Kit (Cat.# AST-9650) offer powerful tools for building off-the-shelf therapies by combining reduced immunogenicity, robust pluripotency, and genome engineering readiness. They are an isogenic match to the forthcoming GMP-grade versions to offer a seamless path from early research to clinical development. Both new research-use-only (RUO) products are reprogrammed from CD34+ umbilical cord blood cells—selected for their low mutational burden and reduced immune activation—and genetically modified to knock out both B2M and CIITA, eliminating cell surface expression of HLA class I and II molecules. This B2M/CIITA double knock-out minimizes the likelihood of T cell-mediated immune rejection, accelerating your allogeneic therapeutic development. "Our latest ActiCells products demonstrate how Applied StemCell's deep expertise in iPSC biology and genome editing enables us to create tools that push the boundaries of what's possible in allogeneic therapy," said Ruby Tsai, Ph.D., CEO of Applied StemCell. "With these new hypoimmunogenic iPSC platforms, researchers have the flexibility to rapidly build, test, and optimize cell therapies that are designed to evade immune rejection." The ActiCells™ RUO Hypo hiPSCs product provides a ready-to-use, transgene-free cell line that is well-characterized, pluripotent, and ready for additional genome engineering. For researchers who require immediate knock-in capabilities, the ActiCells™ RUO TARGATT™ Hypo hiPSC Knock-in Kit includes the same hypoimmunogenic cell line pre-engineered with TARGATT™ large knock-in technology at the H11 safe harbor locus. The kit also includes cloning and integrase plasmids, enabling site-specific insertion of payloads up to 20 kb with reliable expression and minimal risk of gene silencing or off-target effects. "These two complementary products allow researchers to choose the format that best fits their project timelines and resources," said Dr. Tsai. "Whether you're building custom engineered lines in your own lab or partnering with us for iPSC gene editing services, you can count on ActiCells to deliver consistent quality and advanced functionality." For more information, visit: About Applied StemCell Founded in 2008 to provide industry and academic researchers with the ability to leverage the power of induced pluripotent stem cells (iPSC) and gene editing, Applied StemCell continues to use our innovative technologies to power the discovery and development of advanced therapeutics. Our products and services enable the full spectrum of basic research to GMP manufacturing—including disease modeling, iPSC services, mammalian cell line engineering, and nonclinical and pre-IND studies—and our patented technologies ensure a clear IP path to commercialization. View source version on Contacts Media Contact: Pia AbolaDirector of MarketingApplied (408) 457-1312 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
20-05-2025
- Business
- Business Wire
Applied StemCell Launches Two New Hypoimmunogenic hiPSC Products to Accelerate Allogeneic Cell Therapy Development
MILPITAS, Calif.--(BUSINESS WIRE)--Applied StemCell, a CRO/CDMO that blends unique genome editing technology and iPSC expertise, announced the launch of their first hypoimmunogenic hiPSC products which are designed to empower researchers developing next-generation allogeneic cell therapies. The ActiCells™ RUO Hypo hiPSCs (Cat.# ASE-9550) and the ActiCells™ RUO TARGATT™ Hypo hiPSC Knock-in Kit (Cat.# AST-9650) offer powerful tools for building off-the-shelf therapies by combining reduced immunogenicity, robust pluripotency, and genome engineering readiness. They are an isogenic match to the forthcoming GMP-grade versions to offer a seamless path from early research to clinical development. 'With these new hypoimmunogenic iPSC platforms, researchers have the flexibility to rapidly build, test, and optimize cell therapies that are designed to evade immune rejection.' Both new research-use-only (RUO) products are reprogrammed from CD34+ umbilical cord blood cells—selected for their low mutational burden and reduced immune activation—and genetically modified to knock out both B2M and CIITA, eliminating cell surface expression of HLA class I and II molecules. This B2M/CIITA double knock-out minimizes the likelihood of T cell-mediated immune rejection, accelerating your allogeneic therapeutic development. 'Our latest ActiCells products demonstrate how Applied StemCell's deep expertise in iPSC biology and genome editing enables us to create tools that push the boundaries of what's possible in allogeneic therapy,' said Ruby Tsai, Ph.D., CEO of Applied StemCell. 'With these new hypoimmunogenic iPSC platforms, researchers have the flexibility to rapidly build, test, and optimize cell therapies that are designed to evade immune rejection.' The ActiCells™ RUO Hypo hiPSCs product provides a ready-to-use, transgene-free cell line that is well-characterized, pluripotent, and ready for additional genome engineering. For researchers who require immediate knock-in capabilities, the ActiCells™ RUO TARGATT™ Hypo hiPSC Knock-in Kit includes the same hypoimmunogenic cell line pre-engineered with TARGATT™ large knock-in technology at the H11 safe harbor locus. The kit also includes cloning and integrase plasmids, enabling site-specific insertion of payloads up to 20 kb with reliable expression and minimal risk of gene silencing or off-target effects. 'These two complementary products allow researchers to choose the format that best fits their project timelines and resources,' said Dr. Tsai. 'Whether you're building custom engineered lines in your own lab or partnering with us for iPSC gene editing services, you can count on ActiCells to deliver consistent quality and advanced functionality.' For more information, visit: About Applied StemCell Founded in 2008 to provide industry and academic researchers with the ability to leverage the power of induced pluripotent stem cells (iPSC) and gene editing, Applied StemCell continues to use our innovative technologies to power the discovery and development of advanced therapeutics. Our products and services enable the full spectrum of basic research to GMP manufacturing—including disease modeling, iPSC services, mammalian cell line engineering, and nonclinical and pre-IND studies—and our patented technologies ensure a clear IP path to commercialization.
Medscape
14-05-2025
- Health
- Medscape
Potential Antigen for Interstitial Cystitis Identified
LAS VEGAS — Is interstitial cystitis (IC) an autoimmune disorder? New evidence suggests at least for some patients, the answer is yes. Researchers have discovered a potential antigen involved in the development of IC with Hunner lesions, they reported here at the American Urological Association (AUA) 2025 Annual Meeting. Genomic typing suggests certain human leucocyte antigens (HLAs) are associated with this form of the condition, which is marked by inflamed lesions lining the bladder wall, researchers said. 'The HLAs are the gold standard of evidence that a disease is autoimmune,' said Joel N.H. Stern, PhD, professor of urology, neurology, and molecular school of medicine at the Zucker School of Medicine at Hofstra/Northwell in Uniondale, New York, who helped conduct the research. Inna Tabansky Stern, MD, PhD, urology resident at the Renaissance School of Medicine, Stony Brook University, Long Island, New York, and Stern's wife, presented the findings. IC/bladder pain syndrome (IC/BPS) affects eight million women and three million men in the United States, some of whom may also have autoimmune conditions like Sjögren syndrome or Hashimoto disease. A hallmark of the condition is at least 6 weeks of painful urination without any infection. Most people with IC/BPS have no abnormal lesions on their bladder wall. Treatments for Hunner lesions include surgical excisions or triamcinolone injections. The researchers recruited 12 patients with IC/BPS and Hunner lesions and seven without the lesions. They conducted high resolution genomic typing on blood samples from the group and found a higher frequency of two HLA alleles in people with Hunner lesions. 'We figured if we understand the HLAs we can start looking at and maybe identifying an antigen that's driving the whole inflammatory response,' Joel Stern said. One possible antigen is uroplakin, a protein on the bladder wall that appeared to have the ability to bind to HLA molecules. In a modeling analysis, they determined the protein, and the molecules did indeed bind. Should uroplakin prove a driver of Hunner lesions in IC, it might be a target for potential treatments. His lab is exploring the connection further. 'There could be treatments targeting the HLA and the immune response, outcompeting the antigen,' he said. 'There are many possibilities, this does open up a new field within interstitial cystitis.' 'Any genetic evidence linking genotype to phenotype is amazing' to better understand the drivers of IC/BPS, said Catherine Brownstein, MPH, PhD, geneticist at Boston Children's Hospital and assistant professor at Harvard Medical School, Boston. 'That's the way we going to get to biomarkers and genetic guided diagnosis and targeted therapies.' Brownstein and her colleagues reported rare variants in the ATP2C1 and ATP2A2 genes affect the development of IC/BPS. That analysis included 348 people with IC/BPS and 11,981 people without the illness. 'There's no reason to assume everyone has one cause. I don't think it's a simple gene-phenotype association,' Brownstein said. IC/BPS is likely underdiagnosed, given the condition is a diagnosis of exclusion with nonspecific symptoms. Understanding all its causes is urgent, she added; as many as 40% of people with IC/BPS are at risk for suicide. 'It's so incredibly painful, and we still don't know the triggers,' she said. 'The more we're able to throw at this and treat it from multiple angles, the better off patients will be.' Joel Stern, MD, reported receiving funding from the National Institute of Diabetes and Digestive and Kidney Diseases. Brownstein reported having no relevant financial conflicts of interest.
